JP2020525416A - 眼表面障害の治療及び診断 - Google Patents

眼表面障害の治療及び診断 Download PDF

Info

Publication number
JP2020525416A
JP2020525416A JP2019569289A JP2019569289A JP2020525416A JP 2020525416 A JP2020525416 A JP 2020525416A JP 2019569289 A JP2019569289 A JP 2019569289A JP 2019569289 A JP2019569289 A JP 2019569289A JP 2020525416 A JP2020525416 A JP 2020525416A
Authority
JP
Japan
Prior art keywords
heparin
ophthalmic formulation
ophthalmic
ocular surface
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019569289A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020525416A5 (https=
Inventor
ジェイン，サンディープ
ムスヌリ，カールティク
Original Assignee
アドヴァイテ エルエルシー．
アドヴァイテ エルエルシー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アドヴァイテ エルエルシー．, アドヴァイテ エルエルシー． filed Critical アドヴァイテ エルエルシー．
Publication of JP2020525416A publication Critical patent/JP2020525416A/ja
Publication of JP2020525416A5 publication Critical patent/JP2020525416A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2019569289A 2017-06-29 2018-03-01 眼表面障害の治療及び診断 Pending JP2020525416A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762526891P 2017-06-29 2017-06-29
US62/526,891 2017-06-29
US201762575508P 2017-10-22 2017-10-22
US62/575,508 2017-10-22
PCT/US2018/020455 WO2019005222A1 (en) 2017-06-29 2018-03-01 TREATMENT AND DIAGNOSIS OF OCULAR SURFACE DISORDERS

Publications (2)

Publication Number Publication Date
JP2020525416A true JP2020525416A (ja) 2020-08-27
JP2020525416A5 JP2020525416A5 (https=) 2021-05-20

Family

ID=64734716

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019569289A Pending JP2020525416A (ja) 2017-06-29 2018-03-01 眼表面障害の治療及び診断

Country Status (4)

Country Link
US (2) US11058713B2 (https=)
EP (1) EP3644966A4 (https=)
JP (1) JP2020525416A (https=)
WO (1) WO2019005222A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024042858A1 (ja) * 2022-08-23 2024-02-29 株式会社エムズサイエンス 角膜障害治療剤

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230091716A1 (en) * 2020-02-12 2023-03-23 Glia, Llc Progesterone Combinations
DE102020104540A1 (de) * 2020-02-20 2021-08-26 Carl Zeiss Meditec Ag Ophthalmologische Zusammensetzung und Detektionsvorrichtung für ein medizinisches Gerät
US20220160668A1 (en) 2020-11-23 2022-05-26 Sight Sciences, Inc. Formulations and methods for treating conditions of the eye
KR102391198B1 (ko) * 2021-08-27 2022-04-27 한림제약(주) 리피테그라스트 또는 이의 약제학적으로 허용가능한 염을 포함하는 수용액 형태의 점안액 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10161149A1 (de) * 2001-12-12 2003-06-26 Ursapharm Arzneimittel Gmbh Heparin-haltiges Ophthalmikum
CN1459291A (zh) * 2003-05-28 2003-12-03 凌沛学 含低分子肝素的滴眼液及其制备方法
JP2007523912A (ja) * 2004-02-26 2007-08-23 アドバンスト アキュラー システムズ リミテッド 眼病変治療用へパリン

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2207049A (en) * 1987-07-15 1989-01-25 Steven B Siepser Heparin formulation for use in eye surgery
US6231889B1 (en) * 1998-09-21 2001-05-15 Chronorx, Llc Unit dosage forms for the treatment of herpes simplex
JP4682495B2 (ja) * 1999-09-06 2011-05-11 小野薬品工業株式会社 眼疾患の予防、治療剤
CN1394610A (zh) * 2002-07-12 2003-02-05 黄建林 肝素钙眼药水
GB0404693D0 (en) * 2004-03-02 2004-04-07 Univ London Pharmaceutical preparations for the treatment of ocular surface and other disorders
US8372814B2 (en) * 2004-06-07 2013-02-12 Ista Pharmaceuticals, Inc. Ophthalmic formulations and uses thereof
US20060122152A1 (en) * 2004-12-03 2006-06-08 Peyman Gholam A Heparin for the treatment of ocular pathologies
US20060276440A1 (en) * 2005-01-03 2006-12-07 An Wenqian F Treatment of inflammatory disorders
US20080274104A1 (en) * 2005-02-10 2008-11-06 Arlinghaus Ralph B Targeting a Secreted Pro-Apoptotic Factor for Cancer Therapeutics
EP2173163A4 (en) * 2007-07-06 2010-12-08 Glaxosmithkline Llc ANTIBODY FORMULATIONS
US20090253661A1 (en) * 2008-04-04 2009-10-08 Gholam A. Peyman Ocular agents
US9867871B2 (en) * 2011-12-12 2018-01-16 The Board Of Trustees Of The University Of Illinois Composition and method for treating nucleic acid-related eye disease
EP2794550B1 (en) * 2011-12-23 2019-02-20 University of Western Sydney Ophthalmic formulation
RU2535115C1 (ru) * 2013-05-15 2014-12-10 Бости Трейдинг Лтд Фармацевтический состав, содержащий нейротоксин ботулина
EP3094651B1 (en) * 2014-01-14 2020-03-11 Kymab Limited Anti-light antibodies
JP2018524067A (ja) * 2015-06-11 2018-08-30 アットウィル メディカル ソルーションズ インコーポレイテッド アンチトロンビン−ヘパリン組成物を利用する医療機器、システムおよび方法
US20190093165A1 (en) * 2016-02-29 2019-03-28 Santen Sas Gene signature for the prognosis of dry eye disease

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10161149A1 (de) * 2001-12-12 2003-06-26 Ursapharm Arzneimittel Gmbh Heparin-haltiges Ophthalmikum
JP2005513106A (ja) * 2001-12-12 2005-05-12 ウーアザファルマ アールツナイミッテル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント カンパニー カーゲー ヘパリンを保有する眼薬剤
CN1459291A (zh) * 2003-05-28 2003-12-03 凌沛学 含低分子肝素的滴眼液及其制备方法
JP2007523912A (ja) * 2004-02-26 2007-08-23 アドバンスト アキュラー システムズ リミテッド 眼病変治療用へパリン

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J KOREAN OPHTHALMOL SOC, vol. 51, no. 8, JPN6023013118, 2010, pages 1047 - 1053, ISSN: 0005024786 *
第十六改正日本薬局方, JPN6022010818, 2011, pages 1042 - 1044, ISSN: 0005024785 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024042858A1 (ja) * 2022-08-23 2024-02-29 株式会社エムズサイエンス 角膜障害治療剤
JP2024030200A (ja) * 2022-08-23 2024-03-07 株式会社エムズサイエンス 角膜障害治療剤
JP7514033B2 (ja) 2022-08-23 2024-07-10 株式会社エムズサイエンス 角膜障害治療剤

Also Published As

Publication number Publication date
US20210322457A1 (en) 2021-10-21
EP3644966A4 (en) 2021-03-24
EP3644966A1 (en) 2020-05-06
WO2019005222A1 (en) 2019-01-03
US20190000871A1 (en) 2019-01-03
US11058713B2 (en) 2021-07-13

Similar Documents

Publication Publication Date Title
US20210322457A1 (en) Treatment and diagnosis of ocular surface disorders
US9877645B2 (en) Inflammatory eye disorders
JP7624220B2 (ja) 自己抗体媒介性眼疾患の治療および診断
CN113164043B (zh) 用于青光眼的组合物和方法
Schechter et al. Efficacy of topical cyclosporine for the treatment of ocular rosacea
López-Plandolit et al. Efficacy of plasma rich in growth factors for the treatment of dry eye
Ciprandi et al. Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cells: an antiallergic activity
Al-Saedi et al. Dry eye disease: present challenges in the management and future trends
JP2024116245A (ja) 乾性眼疾患の治療のための眼科用組成物
Yavuz et al. Hydroxychloroquine improves dry eye symptoms of patients with primary Sjogren’s syndrome
CN115943314A (zh) 干眼病生物标志物及其治疗用途
CN1964719B (zh) 依碳酸氯替泼诺用于制备治疗干眼症的药物的用途
Monk et al. Detection of endogenous cortisol in equine tears and blood at rest and after simulated stress
KR20170048426A (ko) 시각 장애를 치료하기 위한 조성물 및 방법
WO2022150580A1 (en) Treatment of dry eye disease
US20200054745A1 (en) Methods for treatment of age-related macular degeneration
JP6544806B2 (ja) 眼疾患の治療および診断
Tomida et al. Correlations between tear fluid and aqueous humor cytokine levels in bullous keratopathy
US20150307619A1 (en) Use of C-C Chemokine Receptor Type 7 (CCR7) Inhibitors
RU2845362C2 (ru) Лечение и диагностика опосредованных аутоантителами глазных заболеваний
Qureshi et al. Atopic Keratoconjunctivitis: Diagnosis and Treatment
Yin et al. TGF-β/RhoA/ROCK Signaling Activation Orchestrates Ciliary Body EMT and Fibrosis in Myopia
Kai et al. Evaluation methods using tear volume in a conjunctivitis mice model
Muna et al. Ocular cicatricial pemphigoid
Eguiluz-Gracia et al. Local mucosal allergic disease

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210407

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220621

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221215

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221215

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20230110

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230131

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230201

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230331

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20230404